乙基氯化镁 | 2386-64-3

• 物质功能分类: 有机原料 - 有机金属类化合物 - 有机镁
• 分子结构分类: 有机化合物 - 有机盐 - 有机金属盐
• 中文名称: 乙基氯化镁
• 中文别名: 氯化乙基镁
• 英文名称: Ethylmagnesium chloride
• 英文别名: ethyl magnesium chloride；2,6-dimethylphenyl 4-ethylbenzoate；ethyl magnesiumchloride；chloro(ethyl)magnesium；ethylmagnesiumchloride
• CAS: 2386-64-3
• 化学式: C₂H₅ClMg
• 分子量: 88.8197
• InChiKey: ZWNJJACKPNTXHY-UHFFFAOYSA-M

物化性质

• 沸点：
  66℃
• 密度：
  1.00 g/mL at 20 °C
• 闪点：
  1 °F
• 稳定性/保质期：
  避免与氧化物、水分、碱、酸或空气直接接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1.28
• 重原子数：
  4.0
• 可旋转键数：
  1.0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0.0
• 氢给体数：
  0.0
• 氢受体数：
  0.0

安全信息

• TSCA：
  Yes
• 危险等级：
  4.3
• 危险品标志：
  F,C
• 安全说明：
  S16,S24/25,S26,S30,S33,S36/37/39,S43,S43A,S45,S6A,S7/8
• 危险类别码：
  R14/15,R22,R11,R34,R19
• WGK Germany：
  1
• 海关编码：
  2931900090
• 危险品运输编号：
  UN 3399 4.3/PG 1
• 危险标志：
  GHS02,GHS05,GHS07,GHS08
• 危险性描述：
  H225,H260,H314,H335,H351
• 危险性防范说明：
  P210,P231 + P232,P280,P370 + P378,P402 + P404,P403 + P235
• 储存条件：
  在室温下，请避光密封保存。

SDS

Version 1.4
Regulation (EC) No 1907/2006

---

1 - Product and Company Information

---

Product Name ETHYLMAGNESIUM CHLORIDE SOLUTION,
APPROX. 2.8 M IN TETRAHYDROFURAN

---

2 - Hazards Identification

---

SPECIAL INDICATION OF HAZARDS TO HUMANS AND THE ENVIRONMENT
Highly flammable. Reacts violently with water, liberating
extremely flammable gases. Causes burns.

---

3 - Composition/Information on Ingredients

---

Product Name CAS # EC no Annex I
Index Number
ETHYLMAGNESIUM CHLORIDE SOLUTION, None None None
~2.8 M IN TETRAHYDROFURAN
Ingredient Name Percent CAS # EC no Annex I
Index Number
ETHYLMAGNESIUM CHLORIDE >= 20 2386-64-3 219-206-9 None
<= 25
TETRAHYDROFURAN >= 75 109-99-9 203-726-8 603-025-00-0
(Inhibitor free) <= 80
Symbols: F-Xi
R-Phrases: 11-19-36/37
Highly flammable. May form explosive peroxides. Irritating to eyes
and respiratory system.
Formula C2H5ClMg
Molecular Weight 88,8300 AMU

---

4 - First Aid Measures

---

AFTER INHALATION
If inhaled, remove to fresh air. If not breathing give
artificial respiration. If breathing is difficult, give oxygen.
AFTER EYE CONTACT
FLUKA www.molbase.com
Assure adequate flushing of the eyes by separating the eyelids
with fingers.
AFTER INGESTION
If swallowed, wash out mouth with water provided person is
conscious. Call a physician.

---

5 - Fire Fighting Measures

---

CONDITIONS OF FLAMMABILITY
Reacts with water to liberate flammable and/or explosive gas.
EXTINGUISHING MEDIA
Suitable: Dry chemical powder.
Unsuitable: Do not use water.
SPECIAL RISKS
Specific Hazard(s): Vapor may travel considerable distance to
source of ignition and flash back. Emits toxic fumes under fire
conditions.
Explosion Hazards: Vapor may travel considerable distance to
source of ignition and flash back. Container explosion may occur
under fire conditions.
SPECIAL PROTECTIVE EQUIPMENT FOR FIREFIGHTERS
Wear self-contained breathing apparatus and protective clothing
to prevent contact with skin and eyes.

---

6 - Accidental Release Measures

---

PERSONAL PRECAUTION PROCEDURES TO BE FOLLOWED IN CASE OF LEAK OR SPILL
Evacuate area. Shut off all sources of ignition.
PROCEDURE(S) OF PERSONAL PRECAUTION(S)
Wear self-contained breathing apparatus, rubber boots, and heavy
rubber gloves.
METHODS FOR CLEANING UP
Cover with dry-lime, sand, or soda ash. Place in covered
containers using non-sparking tools and transport outdoors.
Ventilate area and wash spill site after material pickup is
complete.

---

7 - Handling and Storage

---

HANDLING
Directions for Safe Handling: Do not breathe vapor. Do not get
in eyes, on skin, on clothing. Avoid prolonged or repeated
exposure.
STORAGE
Conditions of Storage: Keep tightly closed. Keep away from heat,
sparks, and open flame. Store in a cool dry place.
Incompatible Materials: Do not allow contact with water

---

8 - Exposure Controls / Personal Protection

---

ENGINEERING CONTROLS
Safety shower and eye bath. Use only in a chemical fume hood.
FLUKA www.molbase.com
GENERAL HYGIENE MEASURES
Wash thoroughly after handling.
PERSONAL PROTECTIVE EQUIPMENT
Special Protective Measures: Wear appropriate government approved
respirator, chemical-resistant gloves, safety goggles, other
protective clothing. Faceshield (8-inch minimum).

---

9 - Physical and Chemical Properties

---

Appearance Physical State: Liquid
Color: Dark - brown
Property Value At Temperature or Pressure
pH N/A
BP/BP Range N/A
MP/MP Range N/A
Flash Point - 17,000 °C. Method: closed cup
Flammability N/A
Autoignition Temp N/A
Oxidizing Properties N/A
Explosive Properties N/A
Explosion Limits N/A
Vapor Pressure N/A
SG/Density 0,9780 g/cm3
Partition Coefficient N/A
Viscosity N/A
Vapor Density N/A
Saturated Vapor Conc. N/A
Evaporation Rate N/A
Bulk Density N/A
Decomposition Temp. N/A
Solvent Content N/A
Water Content N/A
Surface Tension N/A
Conductivity N/A
Miscellaneous Data N/A
Solubility N/A

---

10 - Stability and Reactivity

---

STABILITY
Reactions to Avoid: Reacts violently with:
Materials to Avoid: Water, Acids, Alcohols.
HAZARDOUS DECOMPOSITION PRODUCTS
Hazardous Decomposition Products: Carbon monoxide, Carbon dioxide,
Hydrogen chloride gas.

---

11 - Toxicological Information

---

SIGNS AND SYMPTOMS OF EXPOSURE
Coughing, chest pains, difficulty in breathing. Nausea,
dizziness, and headache. Unconsciousness. Material is extremely
destructive to tissue of the mucous membranes and upper
respiratory tract, eyes, and skin. Inhalation may result in
spasm, inflammation and edema of the larynxand bronchi, chemical
pneumonitis, and pulmonary edema. Symptoms of exposure may
include burning sensation, coughing, wheezing, laryngitis,
FLUKA www.molbase.com
shortness of breath, headache, nausea, and vomiting. Narcotic
effect. Exposure can cause: Can cause CNS depression.
ROUTE OF EXPOSURE
Multiple Routes: Harmful if swallowed, inhaled, or absorbed
through skin.
TARGET ORGAN INFORMATION
Central nervous system. Liver. Kidneys.

---

12 - Ecological Information

---

No data available.

---

13 - Disposal Considerations

---

SUBSTANCE DISPOSAL
Under an inert atmosphere, cautiously add the material to dry
butanol in an appropriate solvent. The chemical reaction may be
vigorous and/or exothermic. Provisions must be made for the
venting of large volumes of highly flammable hydrogen and/or
hydrocarbon gases. Neutralize the solution with aqueous acid.
Filter off any solid residues for disposal as hazardous waste.
Burn the liquid portion in a chemical incinerator equipped with an
afterburner and scrubber. Observe all federal, state, and local
environmental regulations.

---

14 - Transport Information

---

RID/ADR
UN#: 3399
Class: 4.3
PG: I
Subrisk: 3
Proper Shipping Name: Organometallic substance,
liquid, water-reactive, flammable
IMDG
UN#: 3399
Class: 4.3
PG: I
Subrisk: 3
Proper Shipping Name: Organometallic substance,
liquid, water-reactive, flammable
Marine Pollutant: No
Severe Marine Pollutant: No
Technical Name: Required
IATA
UN#: 3399
Class: 4.3
PG: I
Subrisk: 3
Proper Shipping Name: Organometallic substance,
liquid, water-reactive, flammable
Inhalation Packing Group I: No
Technical Name: Required

---

15 - Regulatory Information

---

FLUKA www.molbase.com
CLASSIFICATION AND LABELING ACCORDING TO EU DIRECTIVES
INDICATION OF DANGER: F-C
Highly Flammable. Corrosive.
R-PHRASES: 11-14/15-34
Highly flammable. Reacts violently with water, liberating
extremely flammable gases. Causes burns.
S-PHRASES: 7/8-26-30-36/37/39-43-45
Keep container tightly closed and dry. In case of contact with
eyes, rinse immediately with plenty of water and seek medical
advice. Never add water to this product. Wear suitable
protective clothing, gloves, and eye/face protection. In case
of fire, use special powder for metal fire. Never use water. In
case of accident or if you feel unwell, seek medical advice
immediately (show the label where possible).
Caution: Substance not yet fully tested (EU).
COUNTRY SPECIFIC INFORMATION
Germany
WGK: 1
Self-Classification

---

16 - Other Information

---

WARRANTY
The above information is believed to be correct but does not
purport to be all inclusive and shall be used only as a guide. The
information in this document is based on the present state of our
knowledge and is applicable to the product with regard to
appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Inc.,
shall not be held liable for any damage resulting from handling or
from contact with the above product. See reverse side of invoice
or packing slip for additional terms and conditions of sale.
Copyright 2010 Co. License granted to make
unlimitedpaper copies for internal use only.
DISCLAIMER
For R&D use only. Not for drug, household or other uses.
FLUKA www.molbase.com

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

理化性质

乙基氯化镁四氢呋喃溶液呈现灰色至棕褐色，是一种用途广泛的格氏试剂，在药物合成领域有着广泛的应用。

相关反应

1. 在格氏试剂乙基氯化镁中加入适量的氯化锌，并与酮类化合物进行反应，可以高效生成高产率的三级醇，同时减少副反应的发生。

2. 金刚烷酮仅使用乙基氯化镁作为格氏试剂难以获得理想的烷基化效果。然而，通过这种方法可以获得更理想的产品，并且产率较高；加入氯化锂可进一步提高产率至81%。2-烷基-2-金刚烷醇是一种非常有用的光阻剂材料，因此该方法将在各个领域具有广泛的应用前景。

3. 在格氏试剂乙基氯化镁中添加适量的氯化锌可以有效促进醛亚胺的加成反应。

反应信息

• 作为反应物：
  描述：

  乙基氯化镁 在 lead(II) chloride 作用下， 生成 四乙基铅
  参考文献：
  名称：

  Preparation of tetra alkyl lead

  摘要：

  279,106. Daudt, H. W. 1926年10月15日，[会议日期]。四乙基铅是通过镁乙基氯与铅盐作用制备的。例如，将乙基氯加入镁粉中，在含有少量甲基碘和一小片碘的醚的存在下进行。然后，将得到的镁乙基氯溶液与乙醚中的氯化铅悬浮液处理数小时。将产物倒入水中，蒸馏去除醚，通过蒸汽蒸馏得到四乙基铅。根据第91条（3）（a）款公开检查的说明书还包括使用除甲基碘以外的烷基碘。这一主题在已接受的说明书中没有出现。

  公开号：

  US01798593A1
• 作为产物：
  描述：

  氯乙烷 、 alkaline earth salt of/the/ methylsulfuric acid 在 乙醚 作用下， 生成 乙基氯化镁
  参考文献：
  名称：

  Gilman et al., Recueil des Travaux Chimiques des Pays-Bas, 1935, vol. 54, p. 588

  摘要：

  DOI：
• 作为试剂：
  描述：

  苯乙炔 、 叠氮苯 、 二(五氟苯基)亚膦基氯化物 在 乙基氯化镁 作用下， 以 四氢呋喃 为溶剂， 反应 6.75h， 以47%的产率得到4-(bis(perfluorophenyl)phosphino)-1,5-diphenyl-1H-1,2,3-triazole
  参考文献：
  名称：

  C3 对称 ClickPhos 和相关配体的改进一锅法合成：独特的三唑-锌配合物的结构

  摘要：

  使用改进的一锅法制备了许多 ClickPhos 型配体。已经合成了几种 [三(三唑基)-膦] 锌配合物，并通过 X 射线结构分析对其进行了表征。

  DOI：

  10.1002/ejoc.201001505

文献信息

• Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
  申请人：Aslanian G. Robert

  公开号：US20070010513A1

  公开（公告）日：2007-01-11

  Disclosed are compounds of the formula or a pharmaceutically acceptable salt thereof, wherein: M 1 and M 3 are CH or N; M 2 is CH, CF or N; Y is —C(═O)—, —C(═S)—, —(CH 2 ) q —, —C(═NOR 7 )— or —SO 1-2 —; Z is a bond or optionally substituted alkylene or alkenylene; R 1 is H, alkyl, alkenyl, or optionally substituted cycloalkyl, aryl, heteroaryl, heterocycloalkyl or a group of the formula: where ring A is a monoheteroaryl ring; R 1 is optionally substituted alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome nonalcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma or cognition deficit disorders using said compounds, alone or in combination with other agents.

  揭示了以下化合物的结构式或其药学上可接受的盐，其中： M1和M3为CH或N； M2为CH、CF或N； Y为—C(═O)—、—C(═S)—、—(CH2)q—、—C(═NOR7)—或—SO1-2—；Z为键或可选择地取代的烷基或烯基； R1为H、烷基、烯基，或可选择地取代的环烷基、芳基、杂芳基、杂环烷基或下式的基团： 其中环A为单杂芳基环； R1为可选择地取代的烷基、烯基、芳基、杂芳基、环烷基或杂环烷基；其余变量如规范中所定义；使用这些化合物，单独或与其他药剂结合，治疗过敏引起的气道反应、充血、肥胖、代谢综合征、非酒精性脂肪肝病、肝脂肪变性、非酒精性脂肪性肝炎、肝硬化、肝细胞癌或认知缺陷症状的组合物和治疗方法。
• FIBROSIS INHIBITOR
  申请人：Sumitomo Pharmaceuticals Company, Limited

  公开号：EP1479384A1

  公开（公告）日：2004-11-24

  Medicament being useful as a fibrosis inhibitor for organs or tissues, which comprises a compound of the formula (I): wherein Ring Z is optionally substituted pyrrole ring, etc.; W2 is -CO-, -SO2-, optionally substituted C1-C4 alkylene, etc.; Ar2 is optionally substituted aryl, etc.; W1 and Ar1 mean the following (1) and (2): (1) W1 is optionally substituted C1-C4 alkylene, etc.; Ar1 is optionally substituted bicyclic heteroaryl having 1 to 4 nitrogen atoms as ring-forming atoms: (2) W1 is optionally substituted C2-C5 alkylene, optionally substituted C2-C5 alkenylene, etc.; and Ar1 is aryl or monocyclic heteroaryl, which is substituted by carboxyl, alkoxycarbonyl, etc. at the ortho- or meta-position thereof with respect to the binding position of W1, or a pharmaceutically acceptable salt thereof.

  药物作为器官或组织的纤维化抑制剂而有用，包括具有以下式（I）的化合物： 其中环Z是可选择取代的吡咯环等；W2是-CO-，-SO2-，可选择取代的C1-C4烷基等；Ar2是可选择取代的芳基等；W1和Ar1表示如下（1）和（2）： （1）W1是可选择取代的C1-C4烷基等；Ar1是可选择取代的具有1至4个氮原子作为环形成原子的双环杂芳基： （2）W1是可选择取代的C2-C5烷基，可选择取代的C2-C5烯基等；以及 Ar1是芳基或单环杂芳基，其在相对于W1的结合位置的邻位或间位处被羧基，烷氧羰基等取代， 或其药学上可接受的盐。
• FACTOR XIA-INHIBITING PYRIDOBENZAZEPINE AND PYRIDOBENZAZOCINE DERIVATIVES
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20170275282A1

  公开（公告）日：2017-09-28

  The invention relates to substituted pyridobenzazepine and pyridobenzazocine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

  这项发明涉及取代的吡啶苯并脑和吡啶苯并哌啶衍生物，以及其制备方法，还涉及将其用于生产用于治疗和/或预防疾病的药物，特别是心血管疾病，最好是血栓性或血栓栓塞性疾病，水肿，以及眼科疾病。
• (2-hydroxy)ethyl-thioureas useful as modulators of alpha2B adrenergic receptors
  申请人：ALLERGAN SALES, INC.

  公开号：US20020161051A1

  公开（公告）日：2002-10-31

  Compounds of formula (i) and of formula (ii) 1 wherein the symbols have the meaning disclosed in the specification, specifically or selectively modulate &agr; 2B and/or &agr; 2C adrenergic receptors in preference over &agr; 2A adrenergic receptors, and as such are useful for alleviating chronic pain and allodynia and have no or only minimal cardivascular and/or sedatory activity.

  式（i）和式（ii）的化合物 其中符号的含义在说明书中披露，特别或选择性地调节&agr; 2B 和/或&agr; 2C 肾上腺素受体，优先于&agr; 2A 肾上腺素受体，因此对缓解慢性疼痛和触痛有用，并且几乎没有或只有极小的心血管和/或镇静活性。
• Imidazol-4-ylmehanols and their use as inhibitors of steroid C17-20 lyase
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06649643B1

  公开（公告）日：2003-11-18

  Imidazol-4-ylmethanols and their uses for preventing and treating primary tumors, metastasis and recurrence of tumors, various symptoms accompanying tumors, prostatic hypertrophy, virilism, hirsutism, male pattern alopecia, precocious puberty, endometriosis, uterine myoma, mastopathy and polycystic ovary syndrome are disclosed.

  Imidazol-4-ylmethanols及其用于预防和治疗原发性肿瘤、肿瘤转移和复发、伴随肿瘤的各种症状、前列腺肥大、男性化、多毛症、男性型脱发、性早熟、子宫内膜异位症、子宫肌瘤、乳腺病和多囊卵巢综合征的用途被披露。